Application for admission of shares to listing

RNS Number : 0528W

Syncona Limited

17 August 2022

 

Syncona Limited

Application for admission of shares to listing and trading

17 August 2022

Syncona Ltd (the "Company") has retrospectively applied to the Financial Conduct Authority and the London Stock Exchange for 1,892,450 shares to be admitted to the Official List and to trading on the Main Market respectively. The shares were issued in 2014 in satisfaction of the payment of the Company's 2014 scrip dividend, as set out in the RIS announcement made by the Company (then named BACIT Limited) on 10 September 2014, but the applications were not completed at the time. It is expected that admission of the 1,892,450 shares to the Official List will become effective on 19 August 2022.

There will be no change to the existing number of ordinary shares in issue or total number of voting rights in the Company, which both remain at 669,329,324. Disclosures made by the Company since the 2014 dividend issue with regards to the total number of ordinary shares in issue and the total number of voting rights in the Company are unchanged.

[ENDS]

Enquiries

Syncona Ltd
Annabel Clark / Natalie Garland-Collins / Fergus Witt
Tel: [phone]

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com .

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

END

 

 

MSCUVAARUWUWAAR